Mowi ASA will conduct an Extraordinary General Meeting on 20 November 2025. Please find attached the notice to the meeting, including proposal from the Nomination Committee. Mowi's acquisition of Nova Sea AS has been completed, and the Extraordinary General Meeting is held to elect former chair and owner of Nova Sea AS, Aino Olaisen, as a new member of the Board of Directors of Mowi. The Nomination Committee 's recommendation to the Extraordinary General Meeting is that Aino Olaisen is elected as a new memb ...

ING to appoint Ida Lerner as chief financial officer ING announced today that Ida Lerner will be appointed chief financial officer of ING. Until recently, Ida served as chief financial officer at Norwegian bank DNB. She will succeed Tanate Phutrakul who will step down from his position at ING’s Annual General Meeting in April 2026 as announced in July 2025. Effective 1 April 2026, Ida will be appointed as member of the Management Board Banking. The Supervisory Board will propose to shareholders to appoint ...

Core Point - Nasdaq Vilnius has changed the effective date for the delisting of PST Group AB shares from December 31, 2025, to December 12, 2025 [1] Summary by Sections - **Delisting Information** - PST Group AB shares (PTR1L, ISIN code LT0000101446) will be delisted from the Main List after the trading session on December 12, 2025, marking the last day for trading these shares on Nasdaq Vilnius [1]

Core Insights - Jyske Realkredit A/S has approved its financial statement for the first nine months of 2025, indicating a formal acknowledgment of its financial performance during this period [1]. Financial Performance - The financial statement covers the performance metrics and results for the first three quarters of 2025, which are detailed in the attached document [2].

Core Insights - Jyske Bank has raised its profit expectations for 2025 to DKK 4.9bn-5.3bn, up from DKK 3.8bn-4.6bn, driven by positive developments in financial markets and strong credit quality [2][10] - The Danish economy is experiencing growth, with rising employment and housing market activity, while inflation remains controlled [3] Financial Performance - Earnings per share increased by 3% to DKK 62.5 in Q1-Q3 2025 compared to the previous year, despite lower short-term interest rates [2][11] - Core income decreased by 4% to DKK 9,942m, primarily due to a drop in net interest income following a reduction in the policy rate [10][12] - Core expenses fell by 1% to DKK 4,732m, although underlying expenses rose by 1% when adjusted for non-recurring items [10][13] - Loan impairment charges resulted in an income of DKK 22m, reflecting solid credit quality [10][14] Strategic Developments - The company is focusing on enhancing customer experience through investments in digitization and sustainability [4][5] - Jyske Bank has improved its customer satisfaction ratings, ranking first among corporate customers and achieving significant improvements among personal customers [6] - The consolidation of employees in the Glass Cube at Kalvebod Brygge has fostered a stronger professional environment and improved customer advisory services [7] Sustainability Initiatives - Sustainability is increasingly integrated into Jyske Bank's value proposition, with new green products and partnerships to support customers' green transitions [8]

Core Points - Sampo plc has initiated a share buyback program with a maximum limit of EUR 200 million, which commenced on 7 August 2025 [1][2] - On 28 October 2025, Sampo plc acquired a total of 293,553 A shares at an average price of EUR 9.78 per share [1] - Following the transactions, Sampo plc now holds a total of 19,601,134 A shares, representing 0.73% of the total shares outstanding [2] Summary by Category Share Buyback Program - The share buyback program was announced on 6 August 2025 and is in compliance with the Market Abuse Regulation (EU) 596/2014 [1] - The program is based on the authorization granted by Sampo's Annual General Meeting on 23 April 2025 [1] Transaction Details - On 28 October 2025, the daily buyback volumes and average prices were as follows: - AQEU: 1,991 shares at EUR 9.77 - CEUX: 116,530 shares at EUR 9.78 - TQEX: 28,201 shares at EUR 9.79 - XHEL: 146,831 shares at EUR 9.78 - The total buyback volume for the day was 293,553 shares at an average price of EUR 9.78 [1] Ownership Status - After the disclosed transactions, Sampo plc owns 19,601,134 A shares, which is 0.73% of the total number of shares [2]

Core Insights - The company reported satisfactory Q3 results, leading to an upgrade of profit before tax by DKK 150 million, excluding special costs [1] - The CEO highlighted a strong inflow of new customers and progress in the merger of Codan and Alm. Brand, aiming to meet ambitious financial targets for 2025 [1][2] Financial Performance - Guidance for the insurance service result has been raised by DKK 100 million, now specified to DKK 1.75-1.85 billion [3] - Investment result guidance increased by DKK 50 million to DKK 300 million [3] - Q3 2025 insurance service result showed a profit of DKK 535 million, up from DKK 400 million, with a combined ratio improving to 82.2 from 85.7 [3] - Insurance revenue grew by 7.5% to DKK 3,006 million, driven by a 9.9% increase in Personal Lines premiums [3] - The underlying claims experience improved by 3.2 percentage points to 61.4, aided by favorable developments in Commercial Lines [3] - The expense ratio improved to 15.8 from 17.1, reflecting the group's cost-reduction objectives [3] - Synergy initiatives generated a positive accounting effect of DKK 158 million in Q3 2025, with expectations to realize over DKK 600 million in synergies for 2025 [3] - The investment result was satisfactory at DKK 66 million, with shares and bonds contributing positively [3] - Consolidated profit before tax reached DKK 452 million, up from DKK 376 million [3] - The company maintained a high SCR ratio of 254% in Q3 2025 based on PIM approval [3]

Core Points - Addex Therapeutics has issued 34,300,000 new registered shares at a nominal value of CHF 0.01, fully subscribed by its wholly-owned subsidiary, Addex Pharma S.A, to enhance future financing flexibility [1] - The total issued share capital has increased to CHF 2,186,544.96, with a total of 218,654,496 shares issued, while the number of outstanding shares remains unchanged [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2] - Addex has partnered with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [2] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [2] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Core Insights - The company reported significant profitability improvement in its Facility Services businesses, while the Circular Economy Business showed stable performance despite a slight decline in adjusted operating profit [3][4][11]. Financial Performance - For January to September 2025, net sales totaled EUR 571.4 million, a decrease of 0.9% compared to the previous year [6][13]. - Adjusted operating profit for the same period was EUR 37.7 million, up 15.5% from EUR 32.7 million in the previous year [6][13]. - The third quarter net sales were EUR 199.5 million, representing a year-on-year increase of 3.8% [10][17]. - Adjusted operating profit for the third quarter was EUR 20.1 million, slightly up from EUR 20.0 million in the previous year [10][17]. Business Segments Circular Economy Business - Net sales for the Circular Economy Business in January to September were EUR 315.5 million, down from EUR 318.6 million [19]. - Adjusted operating profit for this segment was EUR 31.1 million, a decline from EUR 33.0 million in the previous year [19]. - Demand for recycling and waste management services decreased, particularly in the construction industry [4][20]. Facility Services - Facility Services Finland reported net sales of EUR 170.2 million, down from EUR 179.2 million, but adjusted operating profit improved to EUR 11.1 million from EUR 6.8 million [26][27]. - Facility Services Sweden saw an increase in net sales to EUR 87.3 million from EUR 80.9 million, with adjusted operating results improving to a loss of EUR 2.9 million from a loss of EUR 6.0 million [29][30]. Outlook - The company estimates that net sales in 2025 will be at the same level as in the previous year, with adjusted operating profit projected to be between EUR 44 million and EUR 48 million [2][77]. Sustainability Performance - The company's carbon footprint decreased by 19% compared to the previous year, driven by the use of renewable fuels and investments in a low-emission fleet [8][45]. - Customer satisfaction reached an all-time high with a Net Promoter Score (NPS) of 41 [8][45]. Demerger Plans - The company is preparing for a partial demerger to separate its Circular Economy business into a new publicly listed company, with the plan approved by the Board of Directors on August 7, 2025 [9][75]. - The demerger is subject to approval at an Extraordinary General Meeting scheduled for December 4, 2025, with an effective date planned for December 31, 2025 [9][76].

Core Insights - Corbion reported solid results for the first nine months of 2025, with organic sales growth of +1.2% despite a decline in Q3 [2][5] - Adjusted EBITDA increased by +22.9% year-to-date, reflecting improved operational efficiency and cost-reduction initiatives [2][4] - The company maintains its full-year 2025 guidance, expecting volume/mix growth of +3-5% in Q4 [5] Financial Performance - Total sales for the first nine months of 2025 reached €957.2 million, a decrease of -1.6% compared to the same period in 2024 [2] - Adjusted EBITDA for the first nine months was €156.3 million, up +15.2% year-over-year, with an adjusted EBITDA margin increase of +240 basis points [2][4] - Operating profit for the first nine months was €91.4 million, reflecting an organic increase of +59.6% [2][4] Segment Performance - The Functional Ingredients & Solutions segment maintained sales momentum, although pricing was slightly down due to a pass-through pricing mechanism [3] - In Health & Nutrition, adjusted EBITDA showed excellent growth despite a decline in volume/mix in Q3, attributed to high comparables from Q3 2024 [4] - Positive sales growth was noted in the Pharma business, with expectations for strong volume/mix growth in Health & Nutrition in Q4 [4]